CSCIF (Cosciens Biopharma) Total Liabilities: $3.52 Mil (As of Mar. 2026)

What is Cosciens Biopharma Total Liabilities?

Cosciens Biopharma CSCIF 60 Total Liabilities is $3.52 Mil as of Mar. 2026. GuruFocus rates CSCIF with a GF Score™ of 60/100 and a GF Value™ of $2.36 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Cosciens Biopharma's Total Liabilities for the quarter that ended in Mar. 2026 was $3.52 Mil.

Cosciens Biopharma's quarterly Total Liabilities declined from Sep. 2025 ($18.78 Mil) to Dec. 2025 ($17.59 Mil) and declined from Dec. 2025 ($17.59 Mil) to Mar. 2026 ($3.52 Mil).

Cosciens Biopharma's annual Total Liabilities increased from Dec. 2023 ($2.71 Mil) to Dec. 2024 ($21.91 Mil) but then declined from Dec. 2024 ($21.91 Mil) to Dec. 2025 ($17.59 Mil).

Cosciens Biopharma Total Liabilities Related Terms

Cosciens Biopharma Total Liabilities Historical Data

* Premium members only.

The historical data trend for Cosciens Biopharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosciens Biopharma Total Liabilities Chart

Cosciens Biopharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

2.61

4.01

2.71

21.91

17.59

Cosciens Biopharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															21.00	20.46	18.78	17.59	3.52

60GF Score

Cosciens Biopharma Inc CSCIF

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cosciens Biopharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cosciens Biopharma's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3.613	+	(1.934	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	1.058	+	10.984	+	0)
	=	17.59

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	21.431	-	3.842
	=	17.59

Cosciens Biopharma's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.685	+	(1.837	+	-2.2204460492503E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	3.52

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	18.841	-	15.319
	=	3.52

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of $3.52 Mil mean?

Cosciens Biopharma (CSCIF) has a Total Liabilities of $3.52 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Cosciens Biopharma and its competitors.

Is Cosciens Biopharma's Total Liabilities too high?

Cosciens Biopharma's current Total Liabilities is $3.52 Mil. Overall, Cosciens Biopharma has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Cosciens Biopharma's Total Liabilities compare to VRTX and REGN?

Cosciens Biopharma's Total Liabilities of $3.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Cosciens Biopharma and its competitors. Cosciens Biopharma's current Total Liabilities is $3.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cosciens Biopharma stock overvalued right now?

Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.36, compared to a current price of $1.99 — trading 15.7% below its estimated fair value. The current Total Liabilities is $3.52 Mil. Cosciens Biopharma's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current Total Liabilities is $3.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cosciens Biopharma (CSCIF) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued. The current stock price of $1.99 is trading 15.7% below its estimated GF Value™ of $2.36. GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.

Key valuation signals for CSCIF:

Total Liabilities: $3.52 Mil
GF Value™: $2.36 vs. price of $1.99 (15.7% below fair value)
GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosciens Biopharma Business Description

Industry Healthcare Biotechnology

Comparable Companies XCNQ:GLOW TSXV:MRVL XCNQ:BETR TSXV:KNE TSXV:IOT TSXV:HEM TSX:APS XCNQ:PHRM XCNQ:HEAL TSXV:XRTX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges ET8:Germany CSCI:Canada

Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3

Website https://www.cosciensbio.com

Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.

60GF Score

Get the complete analysis for CSCIF

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.99

Price

$2.36

GF Value

View CSCIF Analysis

See Total Liabilities data for all stocks →